<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738959</url>
  </required_header>
  <id_info>
    <org_study_id>D0190C00008</org_study_id>
    <secondary_id>EUdract NO 2008-001723-56</secondary_id>
    <nct_id>NCT00738959</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability &amp; PK of AZD0328 in Caucasian &amp; Japanese</brief_title>
  <official_title>A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0328 in Healthy Young Japanese and Caucasian Male Volunteers After Oral Single and Multiple Ascending Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be performed to evaluate the safety, tolerability and pharmacokinetics of
      single and multiple doses of AZD0328 when administered to Japanese and Caucasian healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (adverse events, vital signs, paper ECGs and 12-lead continuous digital ECGs including QT/QTc interval measurements</measure>
    <time_frame>During the whole treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK variables</measure>
    <time_frame>Several samples during the study days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0328</intervention_name>
    <description>Oral solution A single dose Day 1 followed by once daily doses on Day 3-7</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first generation Japanese (both parents and grandparents are Japanese, the subject is
             born in Japan and left Japan less than 10 years ago) or Caucasian subjects.

          -  Clinically normal physical findings, laboratory values, vital signs and resting ECG as
             judged by the investigator.

        Exclusion Criteria:

          -  History of clinically significant cardio- or cerebrovascular, pulmonary, renal,
             hepatic, neurological, mental or gastrointestinal disorder or any other major disorder
             that may interfere with the study.

          -  Participation in another study within 12 weeks before the first administration of the
             investigational product.

          -  Intake of any prescribed medicine or herbal remedies based on St John's Wort, except
             for occasional paracetamol and nasal adrenergic anticongestants, within 3 weeks before
             the first administration of the investigational product.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Meulien, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Södertälje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Lorch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Ltd St George's University of London Cranmer Terrace, TootingLondon SW17 ORE UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>October 28, 2008</last_update_submitted>
  <last_update_submitted_qc>October 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Didier Meulien, MD, Medical Science Director, Emerging AD &amp; Cognition</name_title>
    <organization>AstraZeneca R&amp;D, Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>AZD0328</keyword>
  <keyword>Japanese</keyword>
  <keyword>Caucasian</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

